Catalyst Wire Dossier Catalyst Wire Dossier

AVT-02 (adalimumab)

adalimumab · Jamp Pharma Corporation
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AVT-02 (adalimumab), covering 2026-03-17 to 2026-03-17. Get the full timeline:

Most recent: Clinical Trial Update: The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

See pricing